Ontario Teachers Pension Plan Board Has $665,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)

Ontario Teachers Pension Plan Board cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 31.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,855 shares of the biotechnology company’s stock after selling 839 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in United Therapeutics were worth $665,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. grew its holdings in United Therapeutics by 1.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after acquiring an additional 33 shares during the period. Toronto Dominion Bank grew its position in shares of United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 37 shares during the period. ClariVest Asset Management LLC increased its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 42 shares in the last quarter. Finally, First Citizens Bank & Trust Co. boosted its stake in United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 48 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on UTHR. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares of the company’s stock, valued at approximately $1,108,766.10. This trade represents a 70.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher Causey sold 510 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,796 shares of company stock worth $40,936,370. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $367.36 on Friday. The business’s fifty day moving average is $364.39 and its 200-day moving average is $330.59. The stock has a market capitalization of $16.40 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.05 and a beta of 0.56. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the previous year, the firm posted $5.38 earnings per share. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. Research analysts expect that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.